Pages that link to "Q36525116"
Jump to navigation
Jump to search
The following pages link to Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions (Q36525116):
Displaying 50 items.
- Mechanisms of viral entry: sneaking in the front door (Q22252690) (← links)
- A small-molecule dengue virus entry inhibitor (Q22309806) (← links)
- HIV-1 entry inhibitors: an overview (Q24645525) (← links)
- HIV-1 entry inhibitors: recent development and clinical use (Q27003887) (← links)
- HIV entry inhibitors: mechanisms of action and resistance pathways (Q28296162) (← links)
- An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors (Q28477736) (← links)
- Significantly Longer Envelope V2 Loops Are Characteristic of Heterosexually Transmitted Subtype B HIV-1 in Trinidad (Q28478624) (← links)
- Structure of an unliganded simian immunodeficiency virus gp120 core (Q29616089) (← links)
- Closing the door to human immunodeficiency virus. (Q30428089) (← links)
- Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor (Q33223969) (← links)
- Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. (Q33780620) (← links)
- Identification of a small-molecule entry inhibitor for filoviruses (Q33804801) (← links)
- Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity (Q34123595) (← links)
- CD4-induced activation in a soluble HIV-1 Env trimer (Q34510675) (← links)
- Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects (Q34529228) (← links)
- In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. (Q34529347) (← links)
- Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events (Q34545861) (← links)
- Attachment and Fusion Inhibitors Potently Prevent Dendritic Cell-Driven HIV Infection (Q34574462) (← links)
- HIV entry inhibitors and their potential in HIV therapy (Q34595921) (← links)
- Thermodynamics-Based Drug Design: Strategies for Inhibiting Protein–Protein Interactions (Q35190341) (← links)
- HIV-1 entry inhibitors: closing the front door (Q35753350) (← links)
- Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120. (Q35835515) (← links)
- Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. (Q35992805) (← links)
- In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. (Q36086493) (← links)
- Emerging anti-HIV drugs (Q36150601) (← links)
- Emerging drug targets for antiretroviral therapy (Q36237524) (← links)
- N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus (Q36565090) (← links)
- Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41 (Q36643050) (← links)
- Novel inhibitors of the early steps of the HIV-1 life cycle (Q36677383) (← links)
- Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors (Q36681723) (← links)
- Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. (Q36802500) (← links)
- New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists (Q36823525) (← links)
- Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. (Q36824891) (← links)
- Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus (Q36868014) (← links)
- The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors (Q36957295) (← links)
- Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. (Q37010292) (← links)
- Targeting HIV attachment and entry for therapy (Q37034602) (← links)
- Viral drug resistance and fitness. (Q37034618) (← links)
- Vaginal microbicides and the prevention of HIV transmission (Q37063819) (← links)
- Insight into the mechanisms of aminoglycoside derivatives interaction with HIV-1 entry steps and viral gene transcription (Q37273867) (← links)
- Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins (Q37415987) (← links)
- Targeting cell entry of enveloped viruses as an antiviral strategy. (Q37824811) (← links)
- Current and future microbicide approaches aimed at preventing HIV infection in women. (Q37984498) (← links)
- Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors (Q38076139) (← links)
- Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction (Q38090682) (← links)
- Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach (Q38843215) (← links)
- Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors (Q39178072) (← links)
- Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120. (Q39195226) (← links)
- HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. (Q39344552) (← links)
- Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. (Q39351549) (← links)